Gregory J. Divis - 05 Mar 2025 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role: Chief Executive Officer, Director
Signature: /s/ Jerad G. Seurer, as Attorney-in-Fact
Issuer symbol: AVDL
Transactions as of: 05 Mar 2025
Transactions value $: $0
Form type: 4
Filing time: 07 Mar 2025, 16:06:44 UTC
Previous filing: 10 Dec 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVDL	Ordinary Shares	Award	$0	+52K	+32.68%	$0.00	211K	05 Mar 2025	Direct	F1
holding	AVDL	Ordinary Shares						10K	05 Mar 2025	By Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVDL	Stock Option (Right to Buy)	Award	$0	+310K		$0.00	310K	05 Mar 2025	Ordinary Shares	310K	$7.87	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of a restricted share award. The restricted share award shall vest in equal annual installments on each of the first four anniversaries following the 3/5/2025 grant date.
F2	These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary.
F3	The options shall vest, if at all, in four equal increments if the volume-weighted average price of the Issuer's Ordinary Shares during any 30 calendar day period exceeds $11, $14, $17 and $19.09, respectively.